Implementation and clinical benefit of DPYD genotyping in a Danish cancer population

BACKGROUND: In 2020, the European Medicines Agency recommended testing patients for dihydropyrimidine dehydrogenase (DPD) deficiency before systemic treatment with fluoropyrimidines (FP). DPD activity testing identifies patients at elevated risk of severe FP-related toxicity (FP-TOX). The two most u...

Descripción completa

Detalles Bibliográficos
Autores principales: Paulsen, N.H., Pfeiffer, P., Ewertz, M., Fruekilde, P.B.N., Feddersen, S., Holm, H.S., Bergmann, T.K., Qvortrup, C., Damkier, P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10024141/
https://www.ncbi.nlm.nih.gov/pubmed/36791638
http://dx.doi.org/10.1016/j.esmoop.2023.100782

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10024141/
https://www.ncbi.nlm.nih.gov/pubmed/36791638
http://dx.doi.org/10.1016/j.esmoop.2023.100782

Ejemplares similares